TY  - JOUR
AU  - Palmedo, Holger
AU  - Ahmadzadehfar, Hojjat
AU  - Eschmann, Susanne
AU  - Niesen, Andreas
AU  - Schönberger, Johann
AU  - Barsegian, Vahé
AU  - Liepe, Knut
AU  - Mottaghy, Felix M
AU  - Guan, Rongjin
AU  - Pinkert, Joerg
AU  - Sandström, Per
AU  - Herrmann, Ken
TI  - Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 9
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-01321
SP  - 1392-1398
PY  - 2023
N1  - 2023 Sep;64(9):1392-1398
AB  - 223Ra, a targeted α-therapy, is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have bone metastases. In the phase 3 ALSYMPCA study, 223Ra prolonged survival and improved quality of life versus placebo. Our real-world study, PARABO, investigated pain and bone pain-related quality of life in patients with mCRPC and symptomatic bone metastases receiving 223Ra in clinical practice. Methods: PARABO was a prospective, observational, noninterventional single-arm study conducted in nuclear medicine centers across Germany (NCT02398526). The primary endpoint was a clinically meaningful pain response (≥2-point improvement from baseline for the worst-pain item score in the Brief Pain Inventory-Short Form). Results: The analysis included 354 patients, who received a median of 6 223Ra injections (range, 1-6). Sixty-seven percent (236/354) received 5-6 injections, and 33
KW  - 223Ra (Other)
KW  - bone metastases (Other)
KW  - castration-resistant prostate cancer (Other)
KW  - pain response (Other)
KW  - targeted α-therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37385670
DO  - DOI:10.2967/jnumed.123.265557
UR  - https://inrepo02.dkfz.de/record/277292
ER  -